Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew J Muir

Showing results (141-150 of 187) with videos related to

Pageof 19
Sort By:
Journal of Hepatology|September 15, 2014
Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGETStuart C Gordon, Andrew J Muir, Joseph K Lim, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 7, 2022
Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSCMichael Trauner, Christopher L Bowlus, Aliya Gulamhusein, et al.
The American Journal of Gastroenterology|August 30, 2019
Patients With Nonalcoholic Steatohepatitis Experience Severe Impairment of Health-Related Quality of LifeZobair M Younossi, Maria Stepanova, Eric J Lawitz, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 4, 2019
Long-term Benefits of Sustained Virologic Response for Patient-Reported Outcomes in Patients With Chronic Hepatitis C Virus InfectionZobair M Younossi, Maria Stepanova, Andrei Racila, et al.
Contemporary Clinical Trials|July 15, 2018
The Hepatitis C-Alcohol Reduction Treatment (Hep ART) intervention: Study protocol of a multi-center randomized controlled trialRae Jean Proeschold-Bell, Donna M Evon, Christina Makarushka, et al.
Hepatology (Baltimore, Md.)|September 25, 2014
Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis CTariq Ahmad, Philip Yin, Jeffrey Saffitz, et al.
Hepatology (Baltimore, Md.)|February 15, 2012
Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic responseSusanna Naggie, Anu Osinusi, Antonios Katsounas, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 9, 2008
Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis CDavid R Nelson, Vinod Rustgi, Vijayan Balan, et al.
Journal of Clinical Gastroenterology|May 16, 2014
Sustained virologic response rates with telaprevir-based therapy in treatment-naive patients evaluated by race or ethnicitySteven L Flamm, Andrew J Muir, Michael W Fried, et al.
Hepatology (Baltimore, Md.)|November 3, 2011
Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment responseAndrew J Muir, Fred F Poordad, John G McHutchison, et al.
Pageof 19

Showing results (141-150 of 187) with videos related to

Sort By:
Pageof 19
Journal of Hepatology|September 15, 2014
Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGETStuart C Gordon, Andrew J Muir, Joseph K Lim, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 7, 2022
Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSCMichael Trauner, Christopher L Bowlus, Aliya Gulamhusein, et al.
The American Journal of Gastroenterology|August 30, 2019
Patients With Nonalcoholic Steatohepatitis Experience Severe Impairment of Health-Related Quality of LifeZobair M Younossi, Maria Stepanova, Eric J Lawitz, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 4, 2019
Long-term Benefits of Sustained Virologic Response for Patient-Reported Outcomes in Patients With Chronic Hepatitis C Virus InfectionZobair M Younossi, Maria Stepanova, Andrei Racila, et al.
Contemporary Clinical Trials|July 15, 2018
The Hepatitis C-Alcohol Reduction Treatment (Hep ART) intervention: Study protocol of a multi-center randomized controlled trialRae Jean Proeschold-Bell, Donna M Evon, Christina Makarushka, et al.
Hepatology (Baltimore, Md.)|September 25, 2014
Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis CTariq Ahmad, Philip Yin, Jeffrey Saffitz, et al.
Hepatology (Baltimore, Md.)|February 15, 2012
Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic responseSusanna Naggie, Anu Osinusi, Antonios Katsounas, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 9, 2008
Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis CDavid R Nelson, Vinod Rustgi, Vijayan Balan, et al.
Journal of Clinical Gastroenterology|May 16, 2014
Sustained virologic response rates with telaprevir-based therapy in treatment-naive patients evaluated by race or ethnicitySteven L Flamm, Andrew J Muir, Michael W Fried, et al.
Hepatology (Baltimore, Md.)|November 3, 2011
Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment responseAndrew J Muir, Fred F Poordad, John G McHutchison, et al.
Pageof 19